CTI's Pixuvri Strategy After FDA Rejection: Pursue Expanded Access, Start Combination Trial
This article was originally published in The Pink Sheet Daily
FDA's "complete response" letter follows ODAC's vote against the non-Hodgkin's lymphoma drug in March because CTI had insufficient data.
You may also be interested in...
Saving Face? Cell Therapeutics Withdraws Pixantrone NDA Ahead Of Advisory Committee Review
Company’s announcement that it pulled the NDA for its investigational non-Hodgkin’s lymphoma treatment comes after the sponsor would have received FDA’s background briefing document for the Feb. 9 Oncologic Drugs Advisory Committee meeting.
Cell Therapeutics' Dual Strategy On Pixuvri Will Be Tested At Advisory Committee
While appealing the “complete response” letter it got for its non-Hodgkin’s lymphoma treatment Pixuvri on the basis of re-analyzed data, Cell Therapeutics also is doing the additional combination trial the agency requested.
Making Expanded Access Programs Work For - Not Against - Your Trial Drug
Providing an investigational drug outside of a controlled trial carries inherent development risks, but it can also be a win-win proposition for patients and sponsors when managed well, veterans of "expanded access" programs say